2021 FDA inspections at Thermo Fisher Scientific's Greenville plant identified 17 deficiencies, including inadequate sterilization procedures.

Thermo Fisher Scientific's Greenville plant, a major U.S. contract drug manufacturer, has faced multiple regulatory violations over the past decade, particularly concerning contamination and quality control. Recent FDA inspections identified 17 deficiencies, including inadequate sterilization procedures, but no patient harm has been reported. Despite these issues being resolved, experts remain concerned about the facility's manufacturing practices, given its role in producing critical medications.

October 04, 2024
6 Articles